Cocaine Related Disorders Clinical Trial
Official title:
Efficacy of Caffeine, With and Without Biperiden, in the Detoxification of Cocaine Dependent Patients
The aim of this study is to assess the efficacy of caffeine compared to placebo in
detoxifying cocaine dependent patients. Caffeine potentiation with biperiden will be also
studied.
108 with cocaine dependence will be randomized to receive caffeine (300 - 1200 mg t.i.d.)
plus biperidene (8 mg b.i.d.) or caffeine (300 - 1200 mg t.i.d.) with placebo or placebo
during 6 months.
Primary efficacy outcomes will be 1) patient comfort assessed with abstinence
symptomatology, craving for cocaine and mental status during detoxifying period, 2) study
retention and 3) cocaine use.
Brain dopamine system will be assessed thru IBZM-SPECT and the apomorphine test.
Status | Completed |
Enrollment | 85 |
Est. completion date | October 2010 |
Est. primary completion date | December 2009 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 60 Years |
Eligibility |
Inclusion Criteria: - diagnosis of intranasal cocaine dependence, according to DSM-IV-TR criteria - age between 18 and 60 years - current cocaine use, confirmed by a positive urine drug screen for cocaine the week prior to admission. - demonstrated capacity to grant informed consent and sign the pertinent informed consent form. - place of residence compatible with attendance at the centre. - for women, willingness to use effective contraceptive measures during the study. Exclusion Criteria: - diagnosis of a severe medical disorder that could interfere with the study - presence of an organic pathology for which methylxanthines or biperidene, iodine or apomorphine administration is contraindicated - serum liver transaminase levels 3 times higher than normal values - pregnancy and breast-feeding - neuroleptic medication treatment in the past 6 weeks - current treatment, or anticipation that the patient may need to initiate treatment during the study with drugs that may interact with study medication. - current diagnosis of a major mental disorder. - awareness of a situation that could prevent the patient's participation in the study (e.g. serving a sentence) - current participation in another research project. |
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Spain | Hospital Universitari Vall d'Hebron | Barcelona | Catalonia |
Lead Sponsor | Collaborator |
---|---|
Hospital Universitari Vall d'Hebron Research Institute |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | 1) comfort with cocaine detox defined as cocaine abstinence symptoms, cocaine craving, depressive symptoms and anxiety symptoms 2) study retention and 3) cocaine use. | 12-14 days for primary otcome num 1 and 23 weeks for num 2 and 3. | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00535002 -
The Effect of Yohimbine on Cocaine Cue Reactivity
|
N/A | |
Completed |
NCT01815645 -
Contingency Management Treatment for Crack Addiction - Study With Brazilian Population
|
N/A | |
Completed |
NCT00613015 -
Stress and Medication Effects on Cocaine Cue Reactivity
|
Phase 2 | |
Completed |
NCT01392092 -
Effects of N-acetylcysteine on Brain Chemistry and Behavior in Cocaine Abusers (NAC)
|
||
Completed |
NCT00946660 -
Non-Treatment Study of Factors Affecting Cocaine Drug Choice
|
N/A | |
Terminated |
NCT01148992 -
Interactions Between Intravenous (IV) Cocaine and Lofexidine
|
Phase 1 | |
Completed |
NCT01189578 -
Brain Imaging of Cocaine Craving in Recreational Cocaine Users
|
N/A |